To be sold by retail on prescription of Registered Medical Practitioner only
· Non-steroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with CV disease or risk factors for CV disease may be at greater risk.
· Diclofenac sodium tablets are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
· NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including inflammation, bleeding, ulceration and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious GI events.
Each gram of gel contains:
Diclofenac Diethylamine IP Eq. to Diclofenac Sodium……………1.00 % w/w
Virgin Linseed Oil BP…………......................................................3.00% w/w
Methyl Salicylate IP…………........................................................10.00% w/w
Menthol IP…………………….........................................................5.00% w/w
Benzyl Alcohol IP...........................................................................1.00% w/w
In a water washable base..............................................................q.s
Diclofenac Sodium, Methyl Salicylate, Virgin Linseed Oil and Menthol Gel 10g, 20g, 30g, 50g and 75g.
OMNI Gel is indicated for the treatment of pain, swelling and inflammation due to musculo-skeletal disorders (such as sprains, strains, tendonitis, bursitis, hand, neck, shoulder pain, sciatica, muscle stiffness, joint pain, backache and lunage)
Posology and Method of Administration
As directed by physician
· The use of OMNI Gel is contraindicated in patients with a known hypersensitivity to diclofenac and/or any other active ingredient or excipient.
· OMNI Gel should not be administered in patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) or salicylate idiosyncrasy. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.
· OMNI Gel is contraindicated in the setting of Coronary Artery Bypass Grafting (CABG) surgery.
· Product can cause convulsions. Contraindicated in infants below 2 years of age. Caution must be exercised when older children are treated. Avoid direct application into nostrils.
· OMNI Gel is contra-indicated on broken or irritated skin.
Special Warnings and Precautions for Use
Cardiovascular Thrombotic Events
Clinical trials of several cyclooxygenase (COX)-2 selective and non-selective NSAIDs of up to 3 years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction and stroke, which can be fatal. All NSAIDs, both COX-2 selective and non-selective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimise the potential risk for an adverse CV event in patients treated with NSAIDs, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV toxicity and the steps to take if they occur. There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAIDs use. The concurrent use of aspirin and NSAIDs such as diclofenac does increase the risk of serious gastrointestinal (GI) events. Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.
GI Effects – Risk of GI Ulceration, Bleeding and Perforation
NSAIDs, including diclofenac, can cause serious GI events, including bleeding, ulceration and perforation of the stomach, small intestine or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only 1 in 5 patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3–6 months, and in about 2–4% of patients treated for 1 year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.
NSAIDs should be prescribed with extreme caution in patients with a prior history of ulcer disease or GI bleeding. Patients with a prior history of peptic ulcer disease and/or GI bleeding who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared with patients with neither of these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAIDs therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and, therefore, special care should be taken in treating this population.
To minimise the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest possible duration. Physicians and patients should remain alert for signs and symptoms of GI ulceration and bleeding during diclofenac therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. For high-risk patients, alternate therapies that do not involve NSAIDs should be considered.
Elevations of one or more liver tests may occur during therapy with diclofenac sodium. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continued therapy. Borderline elevations (i.e. less than 3 times the ULN) or greater elevations of transaminases occurred in about 15% of diclofenac-treated patients. Of the markers of hepatic function, ALT (SGPT) is recommended for the monitoring of liver injury.
In clinical trials, meaningful elevations (i.e. more than 3 times the ULN) of AST (GOT) (ALT was not measured in all studies) occurred in about 2% of approximately 5,700 patients at some time during diclofenac treatment. In a large, open-label, controlled trial of 3,700 patients treated for 2–6 months, patients were monitored first at 8 weeks and 1,200 patients were monitored again at 24 weeks. Meaningful elevations of ALT and/or AST occurred in about 4% of patients and included marked elevations (i.e. more than 8 times the ULN) in about 1% of the 3,700 patients. In that open-label study, a higher incidence of borderline (less than 3 times the ULN), moderate (3–8 times the ULN), and marked (>8 times the ULN) elevations of ALT or AST was observed in patients receiving diclofenac when compared with other NSAIDs. Elevations in transaminases were seen more frequently in patients with osteoarthritis than in those with rheumatoid arthritis.
Almost all meaningful elevations in transaminases were detected before patients became symptomatic. Abnormal tests occurred during the first 2 months of therapy with diclofenac in 42 of the 51 patients in all trials who developed marked transaminase elevations.
In post-marketing reports, cases of drug-induced hepatotoxicity have been reported in the first month, and in some cases, the first 2 months of therapy, but can occur at any time during treatment with diclofenac. Post-marketing surveillance has reported cases of severe hepatic reactions, including liver necrosis, jaundice, fulfilment hepatitis with and without jaundice, and liver failure. Some of these reported cases resulted in fatalities or liver transplantation.
Physicians should measure transaminases periodically in patients receiving long-term therapy with diclofenac, because severe hepatotoxicity may develop without a prodrome of distinguishing symptoms. The optimum times for making the first and subsequent transaminase measurements are not known. Based on clinical trial data and post-marketing experiences, transaminases should be monitored within 4–8 weeks after initiating treatment with diclofenac. However, severe hepatic reactions can occur at any time during treatment with diclofenac.
If abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g. eosinophilia, rash, abdominal pain, diarrhoea, dark urine, etc.), diclofenac sodium should be discontinued immediately.
To minimise the possibility that hepatic injury will become severe between transaminase measurements, physicians should inform patients of the warning signs and symptoms of hepatotoxicity (e.g. nausea, fatigue, lethargy, diarrhoea, pruritus, jaundice, right upper quadrant tenderness, and ‘flu-like’ symptoms), and the appropriate action patients should take if these signs and symptoms appear. To minimise the potential risk for an adverse liver-related event in patients treated with diclofenac sodium, the lowest effective dose should be used for the shortest duration possible. Caution should be exercised in prescribing diclofenac sodium with concomitant drugs that are known to be potentially hepatotoxic (e.g. antibiotics, anti-epileptics).
NSAIDs, including diclofenac gel, can lead to the onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of cardiovascular events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including diclofenac gel, should be used with caution in patients with hypertension. Blood pressure should be monitored closely during the initiation of therapy with diclofenac gel and throughout the course of therapy.
Congestive Heart Failure and Oedema
Fluid retention and oedema have been observed in some patients treated with NSAIDs, including diclofenac gel. Diclofenac gel should be used with caution in patients with fluid retention or heart failure.
Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pre-treatment state. No information is available from controlled clinical studies regarding the use of diclofenac gel in patients with advanced renal disease. Therefore, treatment with diclofenac gel is not recommended in patients with advanced renal disease. If diclofenac gel therapy is initiated, close monitoring of the patient's renal function is advisable.
As with other NSAIDs, anaphylactoid reactions may occur in patients without prior exposure to diclofenac gel. Diclofenac gel should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs. Emergency help should be sought in cases where an anaphylactoid reaction occurs.
NSAIDs, including diclofenac gel, can cause serious skin adverse events such as, exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations, and the use of the drug should be discontinued at the first appearance of skin rash or any other signs of hypersensitivity. Diclofenac gel should not be applied to open skin wounds, infections, inflammations, or exfoliative dermatitis, as it may affect absorption and tolerability of the drug. Diclofenac gel should not be allowed to come into contact with the eyes or with mucous membranes. The effect of diclofenac gel under occlusive dressings has not been evaluated, and should be avoided.
As with other NSAIDs, diclofenac gel should be avoided in late pregnancy, because it may cause premature closure of the ductus arteriosus.
Diclofenac gel cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to exacerbation of corticosteroid responsive illness. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.
The pharmacological activity of diclofenac in reducing inflammation, and possibly fever, may diminish the utility of these diagnostic signs in detecting infectious complications of presumed non-infectious, painful conditions.
Anaemia is sometimes seen in patients receiving NSAIDs. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoeisis. Patients on long-term treatment with NSAIDs, including diclofenac gel, should have their haemoglobin or haematocrit checked if they exhibit any signs or symptoms of anaemia or blood loss.
NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients being treated with diclofenac gel, who may be adversely affected by alteration in platelet function, such as those with coagulation disorders or patients receiving anticoagulants should be carefully monitored.
Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm, which can be fatal. Since cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, diclofenac gel should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with pre-existing asthma.
Patients should minimize or avoid exposure to natural or artificial sunlight on treated areas because studies in animals indicated topical diclofenac treatment resulted in an earlier onset of ultraviolet light induced skin tumours. The potential effects of diclofenac gel on skin response to ultraviolet damage in humans are not known.
Contact of diclofenac gel with eyes and mucosa, although not studied, should be avoided. Patients should be advised that if eye contact occurs, they should immediately wash out the eye with water or saline and consult a physician if irritation persists for more than an hour.
· Showering/bathing should be avoided for at least 1 hour after the application.
· Patient should wash his/her hands after use, unless the hands are the treated joint. If diclofenac gel is applied to the hand(s) for treatment; patient should not wash the treated hand(s) for at least 1 hour after the application.
· Diclofenac gel should not be applied to open wounds.
· Contact of diclofenac gel with eyes and mucous membranes should be avoided.
· External heat and/or occlusive dressings should not be applied to treated joints.
· Exposure of the treated joint(s) to sunlight should be avoided.
· Diclofenac gel should not be used concomitantly with sunscreens, cosmetics, lotions, moisturizers, insect repellents, or other topical medications on the same skin sites has not been evaluated.
· Concomitant use of diclofenac gel with oral NSAIDs has not been evaluated, and may increase adverse NSAIDs effects.
· Wearing of clothing or gloves should be avoided for at least 10 minutes after applying diclofenac gel.
This product is contraindicated in infants below 2 years of age. Caution must be exercised when older children are treated.
Topical analgesic preparations containing methyl salicylate should be used with caution in patients at increased risk of developing salicylate adverse effects. This product contains methyl salicylate and when applied or rub on to the skin, can be absorbed through the skin into the blood. For patients taking warfarin, excessive application on to the skin for muscle or joint pains may increase the chances of bleeding.
Children suffering from flu, chickenpox, or fever should avoid using this product because salicylates may induce Reyes Syndrome.
When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects.
The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.
NSAIDs may diminish the antihypertensive effect of ACE inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. The response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure as well as to assure diuretic efficacy.
NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs, including diclofenac and lithium, are administered concurrently, patients should be observed carefully for signs of lithium toxicity.
NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs, including diclofenac, are administered concomitantly with methotrexate.
Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs. Therefore, concomitant therapy with diclofenac may increase cyclosporine’s nephrotoxicity. Caution should be used when diclofenac is administered concomitantly with cyclosporine.
Specific interaction studies of diclofenac gel and oral NSAIDs were not performed. Also, the clinical trials of diclofenac gel prohibited concomitant use of oral NSAIDS. There is systemic exposure to diclofenac following normal use of diclofenac gel, up to 6% of the systemic levels of a single oral dose of diclofenac sodium. Therefore, concomitant administration of diclofenac gel with oral NSAIDs or aspirin may result in increased adverse NSAID effects.
Concomitant use of diclofenac gel with other topical products, including topical medications, sunscreens, lotions, moisturisers and cosmetics, on the same skin site has not been tested and should be avoided because of the potential to alter local tolerability and absorption.
This product contains methyl salicylate and when applied or rubbed on to the skin, can be absorbed through the skin into the blood. For patients taking warfarin, excessive application on to the skin for muscle or joints pains may increase the chances of bleeding.
Use in Special Populations
Teratogenic Effects – Pregnancy Category C
The safety of diclofenac gel has not been established during pregnancy. There are no well-controlled studies of diclofenac in pregnant women. Human and animal studies indicate that diclofenac crosses the placenta. In late pregnancy, as with other NSAIDs, diclofenac gel should be avoided because it may cause premature closure of the ductus arteriosus.
Studies in mice, rats, and rabbits in which diclofenac was administered orally throughout gestation revealed no evidence of teratogenicity despite the induction of maternal toxicity and foetal toxicity corresponding to a human equivalent dose approximately 4.5-, 2-, and 9-fold (mouse, rat, and rabbit, respectively) of the maximum human topical dose of diclofenac gel (based on bioavailability and body surface area comparison).
The use of diclofenac, as with other NSAIDs, is associated with the adverse foetal cardiovascular effect of premature closure of the ductus arteriosus.
Safety for use of menthol and methyl salicylate in pregnancy has not been established; therefore, the potential benefit of the product should be weighed against the possible risks to the mother and child.
Labour and Delivery
In rat studies with oral NSAIDs, including diclofenac, as with other drugs known to inhibit prostaglandin synthesis, there is an increased incidence of dystocia and delayed parturition corresponding to a human equivalent dose approximately like the maximum recommended clinical dose (based on bioavailability and body surface area comparison). The effects of diclofenac gel on labour and delivery in pregnant women are unknown.
It is not known whether diclofenac is excreted in human milk; however, studies in animals detected diclofenac in the milk after oral administration. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from diclofenac gel, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Safety for use of menthol and methyl salicylate in lactation has not been established; therefore, the potential benefit of the product should be weighed against the possible risks to the mother and child.
Females and Males of Reproductive Potential
Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including diclofenac sodium topical gel, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. Published animal studies have shown that administration of prostaglandin synthesis inhibitors has the potential to disrupt prostaglandin-mediated follicular rupture required for ovulation. Small studies in women treated with NSAIDs have also shown a reversible delay in ovulation. Consider withdrawal of NSAIDs, including diclofenac sodium topical gel, in women who have difficulties conceiving or who are undergoing investigation of infertility.
Safety and effectiveness in paediatric patients have not been established.
Of the total number of subjects treated with diclofenac gel in clinical studies, 498 were 65 years of age and over. No overall differences in effectiveness or safety were observed between these subjects and younger subjects, but greater sensitivity to the effect of NSAIDs in some older individuals cannot be ruled out. Diclofenac, as with any NSAID, is known to be substantially excreted by the kidneys, and the risk of toxic reactions to diclofenac gel may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken when using diclofenac gel in the elderly, and it may be useful to monitor renal function.
No information is available from controlled clinical studies regarding the use of diclofenac gel in patients with advanced renal disease. Therefore, treatment with diclofenac gel is not recommended in patients with advanced renal disease. If diclofenac gel therapy is initiated, close monitoring of the patient's renal function is advisable.
Elevations of one or more liver tests may occur during therapy with diclofenac sodium. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continued therapy. Borderline elevations (i.e. less than 3 times the ULN or greater elevations of transaminases occurred in about 15% of diclofenac-treated patients. Of the markers of hepatic function, ALT (SGPT) is recommended for the monitoring of liver injury.
To minimise the potential risk for an adverse liver-related event in patients treated with diclofenac sodium, the lowest effective dose should be used for the shortest duration possible. Caution should be exercised in prescribing diclofenac sodium with concomitant drugs that are known to be potentially hepatotoxic (e.g. antibiotics, anti-epileptics).
Effects on Ability to Drive and Use Machines
The following adverse reactions may happen:
· Cardiovascular thrombotic events
· GI bleeding, ulceration and perforation
· Heart failure and oedema
· Renal toxicity and hyperkalaemia
· Anaphylactic reactions
· Serious skin reactions
· Haematologic toxicity
During clinical development, 913 patients were exposed to diclofenac sodium topical gel in randomised, double-blind, multicentre, vehicle-controlled, parallel-group studies in osteoarthritis of the superficial joints of the extremities. Of these, 513 patients received diclofenac sodium topical gel for osteoarthritis of the knee and 400 were treated for osteoarthritis of the hand. Additionally, 583 patients were exposed to diclofenac sodium topical gel in an uncontrolled, open-label, long-term safety trial in osteoarthritis of the knee. Of these, 355 patients were treated for osteoarthritis of 1 knee and 228 were treated for osteoarthritis of both knees. Duration of exposure ranged from 8 to 12 weeks for the placebo-controlled studies, and up to 12 months for the open- label safety trial.
Short-Term, Placebo-Controlled Trials
Adverse Reactions Observed in At Least 1% of Patients Treated with Diclofenac Gel
Non-serious adverse reactions that were reported during the short-term, placebo-controlled studies comparing diclofenac gel and placebo (vehicle gel) over study periods of 8–12 weeks (16 g per day), were application site reactions. These were the only adverse reactions that occurred in >1% of treated patients with a greater frequency in the diclofenac gel group (7%) than the placebo group (2%). Table 1 lists the types of application site reactions reported. Application site dermatitis was the most frequent type of application site reaction and was reported by 4% of patients treated with diclofenac gel, compared to 1% of placebo patients.
N=913, N (%)
N=876, N (%)
Any application site reaction
Application site dermatitis
Application site pruritus
Application site erythema
Application site paraesthesia
Application site dryness
Application site vesicles
Application site irritation
Application site papules
†Preferred term according to MedDRA 9.1
In the placebo-controlled trials, the discontinuation rate due to adverse reactions was 5% for patients treated with diclofenac gel, and 3% for patients in the placebo group. Application-site reactions, including application-site dermatitis, were the most frequent reason for treatment discontinuation.
Long-term, Open-label, Safety Trial
In the open-label, long-term safety study, distribution of adverse reactions was similar to that in the placebo-controlled studies. In this study, where patients were treated for up to 1 year with up to 32 g per day of diclofenac gel, application site dermatitis was observed in 11% of patients. Adverse reactions that led to the discontinuation of the study drug were experienced in 12% of patients. The most common adverse reaction that led to discontinuation of the study was application-site dermatitis, which was experienced by 6% of patients.
Nicolau’s syndrome, also known as livedo-like dermatitis or embolia cutis medicamentosa, is a rare complication reported following intramuscular diclofenac sodium injection.
Menthol and Methyl salicylate
OMNI Gel contain Menthol and Methyl salicylate hence can cause convulsions.
Headache, dizziness, nausea and vomiting, skin irritation, contact dermatitis, rash, itching, redness or swelling, burning or stinging sensation may occur.
May cause hypersensitivity/allergic reactions in some individuals with sensitive skin
If you experience any side effects, talk to your doctor or pharmacist or write to email@example.com. You can also report side effects directly via the National Pharmacovigilance Programme of India (PvPI) by calling on 1800 267 7779 (Cipla number) or you can report to PvPI on 1800 180 3024. By reporting side effects, you can help provide more information on the safety of this product.
There has been no experience of overdose with diclofenac gel.
No events of accidental ingestion have been reported with diclofenac gel. Effects like those observed after an overdose of diclofenac tablets can be expected if substantial amounts of diclofenac gel are ingested.
Symptoms following acute oral NSAID overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. GI bleeding can occur. Hypertension, acute renal failure, respiratory depression, and coma may occur. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur after an overdose.
In the event of oral ingestion resulting in significant systemic side effects, it is recommended that the stomach be emptied by vomiting or lavage. Forced diuresis may theoretically be beneficial because the drug is excreted in the urine.
The effect of dialysis or haemoperfusion in the elimination of diclofenac (99% protein-bound) remains unproven. In addition to supportive measures, the use of oral activated charcoal may help to reduce the absorption of diclofenac. Supportive and symptomatic treatment should be given for complications such as renal failure, convulsions, GI irritation, and respiratory depression.
Symptoms of methyl salicylate overdose
Salicylate intoxication can occur after ingestion or topical application of methyl salicylate Mild chronic salicylate intoxication, or salicylism, usually occurs only after repeated use of large doses. Salicylism can also occur following excessive topical application of salicylates. Symptoms include dizziness, tinnitus, deafness, sweating, nausea and vomiting, headache, and confusion, and may be controlled by reducing the dosage.
Symptoms of more severe intoxication or of acute poisoning following overdose include hyperventilation, fever, restlessness, ketosis, and respiratory alkalosis and metabolic acidosis.
Depression of the CNS may lead to coma; cardiovascular collapse and respiratory failure may also occur.
Symptoms of menthol overdose
Ingestion of significant quantities is reported to cause symptom: severe abdominal pain, nausea, vomiting, vertigo, ataxia, drowsiness, and coma; instant collapse in infants after the local application of menthol to their nostrils.
Seizures may be the first clinical sign of severe toxicity of camphor; however, seizures are usually self-limited. Severe toxicity of camphor can result in delirium, visual hallucinations, cerebral edema, and status epilepticus. Systemic toxicity may include hypotension, tachycardia, respiratory failure, and death.
The stomach should be emptied by gastric lavage or administration of oral activated charcoal Fluid and electrolyte management is the mainstay of treatment with the immediate aim of correction of acidosis, hyperpyrexia, hypokalaemia and dehydration if present. Any convulsions must be controlled first through supportive care including anticonvulsant therapy.
Mechanism of Action
The mechanism of action of diclofenac is similar to that of other NSAIDs. Diclofenac inhibits the enzyme, COX, an early component of the arachidonic acid cascade, resulting in the reduced formation of prostaglandins, thromboxanes and prostacyclin. It is not completely understood how reduced synthesis of these compounds results in therapeutic efficacy.
Menthol dilates the blood vessels causing a sensation of coldness, followed by an analgesic effect. Menthol also acts as a penetration enhancer, increasing the penetration of drugs when applied on the skin, to give a faster onset of action.
Methyl salicylate is a salicylic acid derivative. Salicylates inhibit cyclooxygenase, thereby reducing the formation of prostaglandins, and cause platelet dysfunction. Methyl salicylate is used topically as a counter-irritant. Upon application, it is absorbed through the skin and is applied for the relief of pain in rheumatic conditions and painful muscle or joints.
Diclofenac, the active component of OMNI Gel has anti-inflammatory, anti-nociception, and antipyretic effects. Menthol dilates the blood vessels causing a sensation of coldness, followed by an analgesic effect. Salicylates inhibit cyclooxygenase, thereby reducing the formation of prostaglandins, and cause platelet dysfunction.
The pharmacokinetics of diclofenac gel were assessed in healthy volunteers following repeated applications during 7 days of diclofenac gel to one knee (4 × 4 g per day) or to two knees and two hands (4 × 12 g per day) versus the recommended oral dose of diclofenac sodium for the treatment of osteoarthritis (3 × 50 mg per day). A summary of the pharmacokinetic parameters is presented in Table 2.
Cmax (ng/mL) Mean ± SD
% of Oral (CI)
Mean ± SD
% of Oral (CI)
4 × 4 g per day (=160 mg diclofenac sodium per day)
15 ± 7.3
233 ± 128
Diclofenac gel 4 × 12 g per day (=480 mg diclofenac sodium per day)
53.8 ± 32
807 ± 478
Diclofenac sodium tablets, orally 3 × 50 mg per day (=150 mg diclofenac sodium per day)
2270 ± 778
3,890 ± 1710
Cmax = maximum plasma concentration; tmax = time of Cmax; AUC0–24 = area under the concentration-time curve; SD = standard deviation; CI = confidence interval
Systemic exposure (area under the concentration-time curve) and maximum plasma concentrations of diclofenac are significantly lower with diclofenac gel than with comparable oral treatment of diclofenac sodium.
Systemic exposure with recommended use of diclofenac gel (4 × 4 g per day applied to one knee) is on average 17 times lower than with oral treatment. (Basis: treatment with diclofenac gel of one knee, 4 times a day versus 50 mg, 3 times a day of oral diclofenac tablets). The amount of diclofenac sodium that is systemically absorbed from diclofenac gel is on average 6% of the systemic exposure from an oral form of diclofenac sodium.
The average peak plasma concentration with recommended use of diclofenac gel (4 × 4 g per day applied to one knee) is 158 times lower than with the oral treatment.
The pharmacokinetics of innovator diclofenac gel has been tested under conditions of moderate heat (application of a heat patch for 15 minutes prior to gel application) and of moderate exercise (first gel application followed by a 20-minute treadmill exercise). No clinically relevant differences of systemic absorption and of tolerability were found between applications of diclofenac gel (4 × 4 g per day on one knee) with and under the conditions tested. However, the pharmacokinetics of diclofenac gel was not tested under the condition of heat application following gel application. Therefore, concurrent use of diclofenac gel and heat is not recommended.
Drug Interaction Studies
Aspirin: When NSAIDs were administered with aspirin, the protein-binding of NSAIDs were reduced, although the clearance of free NSAID was not altered. The clinical significance of this interaction is not known.
After absorption, menthol is excreted in the urine and bile as a glucuronide.
May be absorbed through intact skin. The absorption of topical salicylates is proportional to the surface area involved, duration of exposure, concentration and skin integrity. Absorption characteristics of salicylates vary with the dose, formulation and route of administration. Percutaneous absorption is enhanced by exercise, heat, occlusion, or disruption of the integrity of the skin or application to large areas of skin
Both the rate and extent of absorption increases after repeated application; increasing the bioavailability. Methyl salicylate is extensively metabolised to salicylic acid in the dermal and subcutaneous tissues after topical application. At therapeutic levels, the half-life of salicylates is 2-4 hours. As salicylate level increase into the toxic range, the half-life can be greater than 18 hours.
Animal Toxicology or Pharmacology
Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity studies in mice and rats administered diclofenac sodium as a dietary constituent for 2 years at doses up to 2 mg/kg/day (approximately 0.5 and 1 times, respectively, the maximum recommended human topical dose of diclofenac sodium topical gel based on bioavailability and body surface area (BSA) comparison) resulted in no significant increases in tumour.
In a dermal carcinogenicity study conducted in albino mice, daily topical applications of a diclofenac sodium gel product for 2 years at concentrations up to 0.035% diclofenac sodium (a 29-fold lower diclofenac sodium concentration than present in diclofenac sodium topical gel) did not increase neoplasm incidence.
In a photo-carcinogenicity study conducted in hairless mice, topical application of a diclofenac sodium gel product at doses up to 0.035% diclofenac sodium (a 29-fold lower diclofenac sodium concentration than present in diclofenac sodium topical gel) resulted in an earlier median time of onset of tumours incidence.
Diclofenac was not mutagenic or clastogenic in a battery of genotoxicity tests that included the bacterial reverse mutation assay, in vitro mouse lymphoma point mutation assay, chromosomal aberration studies in Chinese hamster ovarian cells in vitro, and in vivo rat chromosomal aberration assay of bone marrow cells.
Impairment of Fertility
Diclofenac did not affect male or female fertility in rats at doses up to 4 mg/kg/day (approximately 2 times than the maximum human topical dose of diclofenac sodium topical gel based on bioavailability and BSA comparison).
OMNI Gel is a NSAID (non-steroidal anti-inflammatory drug) for topical use only. It contains the active ingredient, diclofenac sodium, Methyl Salicylate, Virgin Linseed Oil and Menthol.
As on the pack.
OMNI Gel………………………………………. Tube of 10 g
OMNI Gel………………………………………. Tube of 20 g
OMNI Gel………………………………………. Tube of 30 g
OMNI Gel………………………………………. Tube of 50 g
OMNI Gel………………………………………. Tube of 75 g
Storage and Handling Instructions
Store below 25oC. Do not freeze.
Keep out of reach of children.
· What is OMNI Gel?
OMNI Gel is a topical gel containing diclofenac sodium, Methyl Salicylate, Virgin Linseed Oil and Menthol and is indicated relief of acute musculoskeletal pain and pain of osteoarthritis of joints amenable to topical treatment.
· Do not take if you have an allergy to this drug
Do not use OMNI Gel if you are hypersensitive to diclofenac sodium or/and other NSAIDs or/and methyl salicylate or/and menthol or/and any of the other ingredients of this medicine.
· Before you use OMNI Gel, tell your HCP about other medication.
Some medicines can affect the way other medicines work. Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including the following:
o Aspirin (acetylsalicylic acid) or other NSAIDs (e.g. ibuprofen)
o Medicines known as cyclo-oxygenase-2 (COX2) inhibitors, which are used to treat osteoarthritis or rheumatoid arthritis
o Diuretics (used to treat excess fluid in the body)
o Cyclosporine or tacrolimus (used for immune system suppression, e.g. after transplants)
o Lithium (used to treat some types of depression)
o Digoxin (a medicine for an irregular heart beat and/or heart failure)
o Warfarin or other oral anticoagulants (blood-thinning agents that reduce blood clotting, e.g. aspirin)
o Medicines known as selective serotonin-re-uptake inhibitors (SSRIs), which are used to treat anxiety and depression
o Medicines used to control your blood sugar (oral hypoglycaemics for diabetes)
o Methotrexate (used to treat rheumatoid arthritis, psoriasis and leukaemia)
o Steroid medications (e.g. corticosteroids, which are often used as anti-inflammatory medicines)
o Medicines for high blood pressure (antihypertensives)
o Magnesium containing antacids (used to treat heartburn, indigestion)
o Quinolone antibiotics (used to treat some infections)
o Ketoconazole, fluconazole, miconazole and voriconazole (used to treat some fungal infections)
o Amiodarone (used to treat an abnormal heart beat)
o Sulphinpyrazole (used to treat gout)
o If you have taken a medicine called mifepristone (used to terminate pregnancy) within the last 12 days, diclofenac should not be taken within 8–12 days of taking mifepristone
o Medicines for nausea or sickness, such as metoclopramide or domperidone
o Colestyramine for high cholesterol or high blood fats
o Imatinib, used to treat certain cancers
o Some antibiotics (chloramphenicol)
o concomitant use of diclofenac sodium topical gel with other topical products, including sunscreens, cosmetics, lotions, moisturizers, and insect repellants.
o Any other tablets or medicines, including any not prescribed by your doctor.
· How should I use OMNI Gel?
Always use OMNI Gel exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.
· What are the possible side effects?
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with OMNI Gel. If any of the following happen, stop taking this medicine and tell your doctor immediately:
o CV (cardiovascular) thrombotic events
o GI (gastrointestinal) bleeding, ulceration, and perforation
o Hepatotoxicity (e.g. nausea, fatigue, lethargy, pruritus, diarrhoea, jaundice, right upper quadrant tenderness, and ‘flu-like’ symptoms).
o Anaphylactic reactions (e.g. difficulty breathing, swelling of the face or throat).
o Serious skin reactions
o Heart failure and oedema
o Renal toxicity and hyperkalaemia
o Haematologic toxicity
Headache, dizziness, nausea and vomiting, skin irritation, contact dermatitis, rash, itching, redness or swelling, burning or stinging sensation may occur.
May cause hypersensitivity/allergic reactions in some individuals with sensitive skin.
· How should I store OMNI Gel?
Keep this medicine out of the sight and reach of children.
Store in a dry place and protect from light.
Store in the original packaging.
Do not use this medicine after the expiry date stated on the blister pack and carton. The expiry date refers to the last day of that month.
· General information about the safe and effective use of this drug
OMNI Gel is a topical gel containing diclofenac sodium, Methyl Salicylate, Virgin Linseed Oil and Menthol and is indicated relief of acute musculoskeletal pain and pain of osteoarthritis of joints amenable to topical treatment.
The hands should then be used to gently rub the gel into the skin. After using the dosing card, hold with fingertips, rinse, and dry. If treatment site is the hands, patients should wait at least one hour to wash their hands.
o Avoid showering/bathing for at least 1 hour after the application. Inform patient to wash his/her hands after use, unless the hands are the treated joint. If diclofenac sodium topical gel, 1% is applied to the hand(s) for treatment; inform patient not to wash the treated hand(s) for at least 1 hour after the application.
o Do not apply diclofenac sodium topical gel, 1% to open wounds.
o Avoid contact of diclofenac sodium topical gel, 1% with eyes and mucous membranes.
o Do not apply external heat and/or occlusive dressings to treated joints.
o Avoid exposure of the treated joint(s) to natural or artificial sunlight.
o Avoid concomitant use of diclofenac sodium topical gel, 1% on the treated skin site with other topical products, including sunscreens, cosmetics, lotions, moisturizers, insect repellents, or other topical medications.
o Concomitant use of diclofenac sodium topical gel, 1% with oral non-steroidal anti-inflammatory drugs (NSAIDs) has not been evaluated and may increase adverse NSAIDs effects. Do not use combination therapy with diclofenac sodium topical gel, 1% and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations.
o Avoid wearing of clothing or gloves for at least 10 minutes after applying diclofenac sodium topical gel, 1%.
o This product is contraindicated in infants below 2 years of age. Caution must be exercised when older children are treated.
o Children suffering from flu, chickenpox, or fever should avoid using this product because salicylates may induce Reyes Syndrome.
· What are the ingredients?
OMNI Gel is a topical gel containing diclofenac sodium, Methyl Salicylate, Virgin Linseed Oil and Menthol
· Any other information
o Do not use NSAIDs for a condition for which it was not prescribed.
o Do not give NSAIDs to other people, even if they have the same symptoms that you have. It may harm them.
Mfd. By Cipla Ltd.
Cipla House, Peninsula Business Park,
Ganpatrao Kadam Marg
Mumbai – 400 013, India
M.L. L/17/1905/MNB dated 17/04/2017
M.L. 2/UA/LL/2014 dated 24/07/1998